

responded to gemcitabine: Case report.

World J Gastroenterol. 2010;16:3853-3856.

- 8) Inoue Y, Hiramatsu N, Oze T, Yakushijin T, Mochizuki K, Hagiwara H, Oshita M, Mita E, Fukui H, Inada M, Tamura S, Yoshihara H, Hayashi E, Inoue A, Imai Y, Kato M, Miyagi T, Hoshui A, Ishida H, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi

N.

Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.

J Viral Hepat. 2010;17:336-44.

- G. 知的財産権の出願・登録状況
特になし

IV. 研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
黒崎雅之、 (泉)	B型肝炎に対する 抗ウイルス治療	林紀夫、日 比紀文、上 日紀夫	Annual Review 消化 器	中外医学 社	東京	2011	122-30
田中智大、 (泉)	肝臓癌	佐藤千史、 井上智子	人体の構造と 機能からみた 病態生理	金原出版	東京	2010	93-100
工藤正俊、 (泉)	序文	工藤正俊、 泉並木	ウイルス肝炎 の治療戦略	診断と治 療社	東京	2010	vi-vii
芥田憲夫 (芥田)	肝疾患治療薬 ～ B型・C型肝炎にお ける抗ウイルス療法・ 抗炎症療法	高久史磨	治療薬ハンドブ ック2010	じほう	東京都	2010	513-53 3

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Uemura A, (竹原)	Natural killer cell is a major producer of interferon γ that is critical for the IL-12-induced anti-tumor effect in mice.	Cancer Immunol Immunother	59	453-463	2010
Inoue Y, (竹原)	Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.	J Viral Hepat	17	336-344	2010

Imai Y, (竹原)	Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders.	J Viral Hepat	17	185-191	2010
Sakamori R, (竹原)	STAT3 signaling within hepatocytes is required for anemia of inflammation in vivo.	J Gastroenterol	45	244-248	2010
Yamaguchi S, (竹原)	EphA2-derived peptide vaccine with amphiphilic poly(γ -glutamic acid) nanoparticles elicits an antitumor effect against mouse liver tumor.	Cancer Immunol Immunother	59	759-767	2010
Kohga K, (竹原)	Sorafenib inhibits the shedding of MICA on hepatocellular carcinoma cells by downregulating ADAM9.	Hepatology	51	1264-1273	2010
Shimizu S, (竹原)	The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma.	J Hepatol	52	698-704	2010
Kohga K, (竹原)	Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma.	J Hepatol	52	872-879	2010
Kodama T, (竹原)	Thrombocytopenia exacerbates cholestasis-induced liver fibrosis in mice.	Gastroenterology	138	2487-2498	2010
Ohkawa K, (竹原)	Fatal exacerbation of type B chronic hepatitis triggered by changes in relaxed circular viral DNA synthesis and virion secretion.	Biochem Biophys Res Commun	394	87-93	2010

Ohkawa K, (竹原)	Alteration in hepatitis B virus nucleotide sequences in a chronic virus carrier from immunotolerant to immunoactive phase.	Biochem Biophys Res Commun	394	574-580	2010
Miyagi T, (竹原)	Altered interferon-alpha-signaling in NK cells from patients with chronic hepatitis C virus infection.	J Hepatol	53	424-430	2010
Tomimaru Y, (竹原)	Effects of preceding interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma.	J Surg Oncol	102	308-314	2010
Miyagi T, (竹原)	Absence of invariant natural killer T cells deteriorates liver inflammation and fibrosis in mice fed high-fat diet.	J Gastroenterol	45	1247-1254	2010
Hikita H, (竹原)	The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.	Hepatology	52	1310-1321	2010
Oze T, (竹原)	Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy.	J Hepatol			in press
Tatsumi T, (竹原)	Hepatitis C virus-specific CD8+ T cell frequencies are associated with the responses of pegylated interferon-alfa and ribavirin combination therapy in patients with chronic hepatitis C virus infection.	Hepatol Res	41	30-38	2011
Chayama K, (竹原)	Accumulation of refractory factors for peg-interferon plus ribavirin therapy in older female patients with chronic hepatitis C.	Hepatol Res	40	1155-1167	2010

Tatsumi T, (竹原)	α -galactosylceramide activates antitumor immunity against liver tumor.	Hepatol Res	41	160-169	2011
Inoue Y, (竹原)	Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin.	J Med Virol	83	419-427	2011
Itoh Y, (竹原)	Simple formula to predict response to peginterferon alpha2b and ribavirin combination therapy in genotype 1 chronic hepatitis C patients with high viral loads.	Hepatol Res	41	126-132	2011
Izumi N, (泉)	Predictions of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors.	Hepat Res Treat	In press		2011
Izumi N. (泉)	Recent advances of radiofrequency ablation for early hepatocellular carcinoma.	J Gastroenterol Hepatol	26S	115-22	2011
Asahina Y, (泉)	Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection.	Hepatology	52	518-27	2010
Kurosaki M, (泉)	Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.	J Hepatol	In press		2010
Kurosaki M, (泉)	Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: Data mining analysis.	J Med Virol	In press		2010

Izumi N. (泉)	Diagnostic and treatment algorithm of the Japanese society of Hepatology: a consensus-based practice guideline.	Oncology	78	78-86	2010
Kurosaki M, (泉)	Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy.	Hepatol Res	40	870-7	2010
Yokosuka O, (泉)	Management of hepatitis B: consensus of the Japan Society of Hepatology 2009.	Hepatol Res	41	1-21	2011
Chayama K, (泉)	Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C.	Hepatol Res	40	1155-67	2010
Kurosaki M, (泉)	Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis.	J Gastroenterol	In press		2010
Karino Y, (泉)	Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B.	Hepatol Int	4	414-22	2010
Namiki I, (泉)	Management of hepatitis C; report of the consensus meeting at the 45 th annual meeting of the Japan Society of Hepatology (2009).	Hepatol Res	40	347-68	2010
Kumada H, T (泉)	Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan.	Hepatol Res.	40	1-7	2010

Kurosaki M, (泉)	A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis.	Hepatol Res	40	251-60	2010
Watanabe S, (泉)	Prolonged treatment with pegylated interferon alpha2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan.	Hepatol Res	40	135-44	2010
Itakura J, (泉)	Reproducibility and usability of chronic virus infection model using agent-based simulation; comparing with a mathematical model.	Biosystems	99	70-8	2010
泉 並木 (泉)	ペグインターフェロン・リバビリン併用療法とその効果予測	Current Therapy	28	25-29	2010
泉 並木 (泉)	ウイルス性慢性肝炎の最近の治療	日本医事新報	4500	59-64	2010
泉 並木 (泉)	データマイニングによる病態解析	最新医学	65	1901-6	2010
泉 並木 (泉)	肝疾患の地域連携計画	肝胆膵	61	847-52	2010
Yasui K, (伊藤)	Steatosis and hepatic expression of genes regulating lipid metabolism in Japanese patients infected with hepatitis C virus	J Gastroenterol	45	95-104	2010
Park H, (伊藤)	Hepatic senescence marker protein-30 is involved in the progression of nonalcoholic fatty liver disease	J Gastroenterol	45	426-434	2010
Tsuji K, (伊藤)	PEG10 is a probable target for the amplification at 7q21 detected in hepatocellular carcinoma	Cancer Genet Cytogenet	198	118-125	2010

Nakajima T, (伊藤)	Nuclear size measurement is a simple method for the assessment of hepatocellular aging in non-alcoholic fatty liver disease: comparison with telomere-specific quantitative FISH and p21 immunohistochemistry	Pathol Int	60	175-183	2010
Namiki I, (伊藤)	Management of hepatitis C; Report of the consensus meeting at the 45 th annual meeting of Japan Society of Hepatology (2009)	Hepatol Res	40	347-368	2010
Yamaguchi K, (伊藤)	Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline deficient diet-fed mice	Lab Invest	90	1169-1178	2010
Fujii H, (伊藤)	Relapse of Hepatitis C in a Peginterferon alpha2b plus Ribavirin-Treated Sustained Virological Responder	Hepatol Res	40	654-660	2010
Sumida Y, (伊藤)	Lower circulating levels of dehydroepiandrosterone, independent of insulin resistance, is an important determinant of severity of nonalcoholic steatohepatitis in Japanese patients	Hepatol Res	40	901-910	2010
Park H, (伊藤)	The fatty acid composition of plasma cholesteryl esters and estimated desaturase activities in patients with nonalcoholic fatty liver disease and the effect of long-term ezetimibe therapy on these levels	Clin Chim Acta	411	1735-1740	2010

Itoh Y, (伊藤)	A Simple and Convenient Formula to Predict the Response to Peginterferon alpha2b and Ribavirin Combination Therapy in Genotype 1 Chronic Hepatitis C Patients with High Viral Loads	Hepatol Res	in press		
Mizukoshi E, (金子)	Comparative analysis of various tumor-associated antigen-specific T cell responses in patients with hepatocellular carcinoma.	Hepatology			(in press)
Kurosaki M, (金子)	Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.	J Hepatol			(in press)
Sunagozaka H, (金子)	Identification of a secretory protein c19orf10 activated in hepatocellular carcinoma.	Int J Cancer			(in press)
Misu H, (金子)	A liver-derived secretory protein, selenoprotein P, causes insulin resistance.	Cell Metab	12(5)	483-95	2010
Honda M, (金子)	Differential interferon signaling in liver lobule and portal area cells under treatment for chronic hepatitis C.	J Hepatol	53(5)	817-26	2010
Shirasaki T, (金子)	La protein required for internal ribosome entry site-directed translation is a potential therapeutic target for hepatitis C virus replication.	J Infect Dis	202(1)	75-85	2010
Yamashita T, (金子)	Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation.	Cancer Res	70(11)	4687-97	2010

Honda M, (金子)	Differential gene expression profiling in blood from patients with digestive system cancers.	Biochem Biophys Res Commun	400(1)	7-15	2010
Honda M, (金子)	Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.	Gastroenterology	139(2)	499-509	2010
Ootsuji H, (金子)	Altered hepatic gene expression profiles associated with myocardial ischemia.	Circ Cardiovasc Genet	3(1)	68-77	2010
Hodo Y, (金子)	Comprehensive gene expression analysis of 5'-end of mRNA identified novel intronic transcripts associated with hepatocellular carcinoma.	Genomics	95(4)	217-23	2010
Takatori H, (金子)	dUTP pyrophosphatase expression correlates with a poor prognosis in hepatocellular carcinoma.	Liver Int	30(3)	438-46	2010
Komura T, (金子)	CD14+ monocytes are vulnerable and functionally impaired under endoplasmic reticulum stress in patients with type 2 diabetes.	Diabetes	59(3)	634-43	2010
Marubashi S, (永野)	Salvage cystic duct anastomosis using a magnetic compression technique for incomplete bile duct reconstruction in living donor liver transplantation.	Liver Transpl	16(1)	33-37	2010
Marubashi S, (永野)	Evaluation of a new immunoassay for therapeutic drug monitoring of tacrolimus in adult liver transplant recipients.	Journal of Clinical Pharmacology	50(6)	705-709	2010
Kobayashi S, (永野)	GBP2 mRNA in peripheral blood leukocytes of liver transplant recipients as a marker for acute cellular rejection.	Transplant Immunol.	23(4)	390-396	2010

Okuyama M, (永野)	ROLE of the liver in determining allo-immune response in-vitro following donor-specific spleen cells injection.	Transplant Immunol	22(3-4)	150-156	2010
Tomimaru Y, (永野)	Effects of preceding interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma	J of Surg Oncol.	102	308-314	2010
Ohmura Y, (永野)	Combined-transplantation of pancreatic islets and adipose tissue-derived stem cells enhances the survival and insulin-function of islet grafts in diabetic mice.	Transplantation.	90(12)	1366-1373	2010
Kobayashi S, (永野)	Successful adult ABO incompatible living donor liver transplantation: Experience with double infusion through the hepatic artery and portal vein.	Hepatogastroenterol	in press	in press	2010
Marubashi S, (永野)	Calcineurin Inhibitor for Living Donor Liver Transplant Recipients with Preoperative Renal Dysfunction.	Hepatogastroenterol	in press	in press	2010
永野浩昭, (永野)	特集:肝移植の画像診断 -生体ドナーの安全とレシピエントの予後向上を目指して	生体ドナーに必要な術前画像診断 肝胆膵画像	12(1)	25-32	2010
Naoya Sakamoto, (坂本)	Association of IL28B polymorphism with response to pegylated-interferon alpha plus ribavirin combination therapy in patients with chronic genotype 2 hepatitis C.	J Med Virol	in press		2010
Machi Yamamoto, (坂本)	Studies on virus kinetics using infectious fluorescence-tagged hepatitis C virus cell culture.	Hepatol Res	in press		2011

Xiu Zheng, (坂本)	Suppression of hath1 gene expression directly regulated by hes1 via notch signaling is associated with goblet cell depletion in ulcerative colitis.	Inflamm Bowel Dis	in press		2011
Iwasaki M, (坂本)	Longitudinal cell formation in the entire human small intestine is correlated with the localization of Hath1 and Klf4.	J Gastroenterol			2010
Masayuki Kurosaki, (坂本)	Sequences in the Interferon Sensitivity Determining Region and Core Region of Hepatitis C Virus Impact Pretreatment Prediction of Response to Peg-interferon Plus Ribavirin: Data Mining Analysis.	J Med Virol	in press		2011
Masayuki Kurosaki, (坂本)	Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis.	J Gastroenterol			2010
Masayuki Kurosaki, (坂本)	Pre-treatment Prediction of Response to Pegylated-Interferon Plus Ribavirin for Chronic Hepatitis C using Genetic Polymorphism in IL28B and Viral Factors.	J Hepatol	in press		2010
Naoya Sakamoto, (坂本)	ITPA gene variant protects against anemia induced by pegylated interferon-alfa and ribavirin therapy for Japanese patients with chronic hepatitis C.	Hepatol Res	40(11)	1063-1071	2010
Kaori kameyama, (坂本)	IL-2 is positively involved in the development of colitogenic CD4+ IL-7R α high memory T cells in chronic colitis.	Eur J Immunol	40(9)	2423-2436	2010
Goki Suda, (坂本)	IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones.	Virology	407	80-90	2010

Yuko Karakama, (坂本)	Inhibition of HCV replication by a specific inhibitor of serin-arginine-rich protein kinase.	Antimicrob Agents Chemother	54(8)	3179-3186	2010
Kako Mishima, (坂本)	Cell culture and in vivo analyses of cytopathic hepatitis C virus mutants.	Virology	405	361-369	2010
Mina Nakagawa, (坂本)	Mutations in the Interferon Sensitivity Determining Region and virological response to combination therapy with Pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection.	J Gastroenterol	45(6)	656-665	2010
Yuki Nishimura-Sakurai, (坂本)	Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells.	J Gastroenterol	45(5)	523-536	2010
KyeongJin Kim, (坂本)	Curcumin inhibits hepatitis C virus replication via suppressing the Akt-SREBP-1 pathway.	FEBS Letter	584(4)	707-712	2010
Tomokazu Mizui, (坂本)	Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy.	J Gastroenterol	45(2)	195-203	2010
坂本直哉 (坂本)	新しいインターフェロン製剤：PEG インターフェロンλを中心に	肝胆膵	61(6)	955-958	2011
箴島裕子、 (坂本)	HCVの複製・増殖機構と遺伝子型・遺伝子変異	日本臨床	in press		2011
坂本直哉 (坂本)	インターロイキン 28-29 (IL-28・IL-29) -インターフェロンλ.	臨床免疫・アレルギー科	in press		2011
箴島裕子、 (坂本)	C型肝炎の日常診療:治療の適応、選択の実際	medicina	47(3)	2010-2103	2010
坂本直哉 (坂本)	新規治療薬の開発動向	最新医学	65(9)	1919-1924	2010
坂本直哉 (坂本)	STAT-C(Specifically Targeted Antiviral Therapy for hepatitis C)開発の動向	肝胆膵	2010 増刊号	204-208	2010
坂本直哉 (坂本)	膵癌における TGF-β シグナル伝達系の関与	肝胆膵	61(1)	67-72	2010

坂本直哉, (坂本)	肝疾患における血液生 化学検査, 肝炎ウイルス マーカー, 腫瘍マーカー の見方 IL28B	肝胆膵	60(4)	657-660	2010
植山真由美, (坂本)	IL-6 と肝炎・肝発癌.	肝胆膵	60(5)	849-856	2010
Akuta N, (芥田)	Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to Telaprevir with peginterferon and ribavirin	Hepatology	52(2)	421-429	2010
Kobayashi M, (芥田)	Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b.	J Med Virol	82	41-48	2010
Suzuki F, (芥田)	Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.	J Clin Virol	47(1)	76-78	2010
Arase Y, (芥田)	Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus.	J Med Virol	82	390-395	2010
Kobayashi M, (芥田)	Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment.	Hepatol Res	40(2)	125-134	2010
Hosaka T, (芥田)	Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants.	Hepatol Res	40(2)	145-152	2010

Akuta N, (芥田)	Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin.	J Med Virol	82	575-582	2010
Akuta N, (芥田)	Extending combination therapy with peginterferon plus ribavirin for genotype 2 chronic hepatitis C virological responders: a pilot study of 7 cases.	Intervirology	53	188-192	2010
Arase Y, (芥田)	Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load.	Internal Med	49	957-963	2010
Suzuki F, (芥田)	Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients.	Hepatol Res	25	892-898	2010
Hosaka T, (芥田)	HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy.	Liver Int	93(3-4)	109-112	2010
Kawamura Y, (芥田)	New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma.	Hepatol Res	40(10)	1006-1014	2010
Ikeda K, (芥田)	Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancer.	Hepatol Res	40(12)	1168-1175	2010

Kawamura Y, (芥田)	Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients.	Am J Med	123(10)	951-956	2010
Hashimoto Y, (芥田)	Clinical and virological effects of long-term (over 5 years) lamivudine therapy.	J Med Virol	82	684-691	2010
Suzuki Y, (芥田)	Association of HLA-DR14 with Treatment Response in Japanese Patients with Autoimmune Hepatitis.	Dig Dis Sci	55	2070-2076	2010
Hayes CN, (芥田)	HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.	Gut	in press	in press	2010
瀬崎ひとみ, (芥田)	C型慢性肝炎に対するヘグインターフェロンとリバビリン併用療法におけるNS3-4Aプロテアーゼ阻害剤 (Telaprevir)併用12週間治療のウイルス学的効果の検討	肝臓	51(7)	394-396	2010
八辻寛美, (芥田)	核酸アナログ未使用のB型慢性肝炎症例へのエンテカビル治療中にrtA181Tウイルスが増殖した一症例	肝臓	51(4)	196-198	2010
小林万利子, (芥田)	IL28B と HCV Core aa70 置換との関連	肝臓	51(6)	322-323	2010
Kainuma M, (野村)	Pegylated interferon α -2b plus ribavirin for older patients with chronic hepatitis C.	World J Gastroenterol.	16	4400-4409	2010
Uemura A, (林)	Natural killer cell is a major producer of interferon γ that is critical for the IL-12-induced anti-tumor effect in mice.	Cancer Immunol Immunother	59	453-463	2010

Inoue Y, (林)	Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.	J Viral Hepat	17	336-344	2010
Imai Y, (林)	Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders.	J Viral Hepat	17	185-191	2010
Sakamori R, (林)	STAT3 signaling within hepatocytes is required for anemia of inflammation in vivo.	J Gastroenterol	45	244-248	2010
Yamaguchi S, (林)	EphA2-derived peptide vaccine with amphiphilic poly(γ -glutamic acid) nanoparticles elicits an antitumor effect against mouse liver tumor.	Cancer Immunol Immunother	59	759-767	2010
Kohga K, (林)	Sorafenib inhibits the shedding of MICA on hepatocellular carcinoma cells by downregulating ADAM9.	Hepatology	51	1264-1273	2010
Shimizu S, (林)	The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma.	J Hepatol	52	698-704	2010
Kohga K, (林)	Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma.	J Hepatol	52	872-879	2010

Kodama T, (林)	Thrombocytopenia exacerbates cholestasis-induced liver fibrosis in mice.	Gastroenterology	138	2487-2498	2010
Ohkawa K, (林)	Fatal exacerbation of type B chronic hepatitis triggered by changes in relaxed circular viral DNA synthesis and virion secretion.	Biochem Biophys Res Commun	394	87-93	2010
Ohkawa K, (林)	Alteration in hepatitis B virus nucleotide sequences in a chronic virus carrier from immunotolerant to immunoactive phase.	Biochem Biophys Res Commun	394	574-580	2010
Miyagi T, (林)	Altered interferon-alpha-signaling in NK cells from patients with chronic hepatitis C virus infection.	J Hepatol	53	424-430	2010
Miyagi T, (林)	Absence of invariant natural killer T cells deteriorates liver inflammation and fibrosis in mice fed high-fat diet.	J Gastroenterol	45	1247-1254	2010
Hikita H, (林)	The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.	Hepatology	52	1310-1321	2010
Oze T, (林)	Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy.	J Hepatol			in press
Tatsumi T, (林)	Hepatitis C virus-specific CD8+ T cell frequencies are associated with the responses of pegylated interferon-alfa and ribavirin combination therapy in patients with chronic hepatitis C virus infection.	Hepatol Res	41	30-38	2011

Tatsumi T, (林)	α -galactosylceramide activates antitumor immunity against liver tumor.	Hepatol Res	41	160-169	2011
Inoue Y, (林)	Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin.	J Med Virol	83	419-427	2011
Sakamori R, (平松)	STAT3 signaling within hepatocytes is required for anemia of inflammation in vivo.	J Gastroenterol.	45(2)	244-8	2010
Miyagi T, (平松)	Altered interferon-alpha-signaling in natural killer cells from patients with chronic hepatitis C virus infection.	J Hepatol.	53(3)	424-430	2010
Hayashi N, (平松)	Interferon therapy and new antiviral drugs for chronic hepatitis C.	JMAJ.	53(4)	1-7	2010
小瀬 嗣子, (平松)	難治性 C 型肝炎に対する peg-IFN/RBV 併用療法における非著効例の対策	消化器内科	50(6)	559-564	2010
Inoue Y, (三田)	Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin.	J Med Virol.	83	419-427	2011
Ikura Y, (三田)	Hepatocellular carcinomas can develop in simple fatty livers in the setting of oxidative stress.	Pathology	43	167-168	2011
Oze T, (三田)	Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy.	J Hepatol.			in press